Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT.
Ye Y, Labopin M, Chen J, Wu D, Gedde-Dahl T Sr, Blaise D, Socie G, Forcade E, Salmenniemi U, Maury S, Versluis J, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Shi J, Ciceri F, Huang H, Mohty M, Gorin NC.
Ye Y, et al.
Blood Cancer J. 2024 May 27;14(1):85. doi: 10.1038/s41408-024-01072-0.
Blood Cancer J. 2024.
PMID: 38802349
No abstract available.